Table 3 Safety and adverse events
Placebo (N = 22) | Empagliflozin (N = 20) | |
|---|---|---|
Adverse events | 10 | 5 |
Serious adverse events | 4 | 6 |
Hypoglycemic events | 2 | 4 |
Death | 0 | 0 |
Adverse event leading to discontinuation of a study drug | 0 | 1 |
Acute renale failure | 0 | 0 |
Event consistent with volume depletion | 0 | 3 |
Thromboembolic event | 0 | 1 |
Diabetic ketoacidosis | 0 | 0 |
Urinary tract infection | 0 | 1 |
Genital infection | 0 | 4 |
Bone fracture | 0 | 0 |